S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Investigation on Behalf of InVivo Therapeutics Holdings Corp. Investors Announced by Kirby McInerney LLP|
|INVESTOR ALERT: Class Action Lawsuit Against InVivo Therapeutics Holdings Corp. Announced by Glancy Binkow & Goldberg LLP|
|Shapiro Haber & Urmy LLP Announces It Filed the Securities Fraud Class Action Lawsuit Against InVivo Therapeutics Holdings Corp. (NVIV) (2014/8/5)|
|SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in InVivo Therapeutics Holdings Corp. to Contact the Firm Before the October 6, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- NVIV (2014/8/6)|
|SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in InVivo Therapeutics Holdings Corp. to Contact the Firm Before the Lead Plaintiff Deadline in Class Action Lawsuit -- NVIV (2014/8/4)|
|Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Class Action Lawsuit on Behalf of InVivo Therapeutics Holdings Co. Investors Has Been Filed in the United States District Court for the District of Massachusetts -- NVIV|
|SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against InVivo Therapeutics Holdings Corp. and Its Board of Directors and a Lead Plaintiff Deadline of October 6, 2014 -- NVIV|
|InVivo Therapeutics Receives Notice of Allowance on Patent Covering Neuro-Spinal Scaffold and Neuro-Spinal Scaffold Plus Stem Cells|
|InVivo Therapeutics CEO Mark Perrin in Featured Interview on The Wall Street Transcript|
|InVivo Therapeutics Reports 2014 Second Quarter Financial Results and Business Update|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
Click above to view more mutual fund data and stats for nviv - InVivo Therapeutics Holdings Corp.